Calmodulin binds HER2 and modulates HER2 signaling

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 5, 2011, Pages 1074-1082

  White, Colin D ^a   Li, Zhigang ^a   Sacks, David B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast cancer; Calmodulin; HER2

Indexed keywords

CALCIUM BINDING PROTEIN; CALMODULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CELL GROWTH; CONTROLLED STUDY; DELETION MUTANT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CALCIUM; CALMODULIN; CELL PROLIFERATION; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955646433     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.12.016     Document Type: Article

References (49)

1. Hynes N.E., Lane H.A. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
3. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
4. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232:123-138.
5. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER2/Neu oncogene. Science 1987, 235:177-182.
6. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
7. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11:495-505.
8. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
9. Dankort D., Jeyabalan N., Jones N., Dumont D.J., Muller W.J. Multiple ErbB2/Neu phosphorylation sites mediate transformation through distinct effector proteins. J. Biol. Chem. 2001, 276:38921-38928.
10. Hoeflich K.P., Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell 2002, 108:739-742.
11. Li L., Sacks D.B. Functional interactions between calmodulin and estrogen receptor α. Cell. Signal. 2007, 19:439-443.
12. Graves C.B., Goewert R.R., McDonald J.M. The insulin receptor contains a calmodulin binding domain. Science 1985, 230:827-829.
13. Sacks D.B., Fujita-Yamaguchi Y., Gale R.D., McDonald J.M. Tyrosine-specific phosphorylation of calmodulin by the insulin receptor kinase purified from human placenta. Biochem. J. 1989, 263:803-812.
14. Bouhoute A., Leclercq G. Estradiol derivatives bearing the side chain of tamoxifen antagonize the association between the estrogen receptor and calmodulin. Biochem. Pharmacol. 1994, 47:748-751.
15. 2+-calmodulin. Mol. Endocrinol. 1988, 2:167-174.
16. Li Z., Joyal J.L., Sacks D.B. Calmodulin enhances the stability of the estrogen receptor. J. Biol. Chem. 2001, 276:17354-17360.
17. 2+/calmodulin. Nature 2001, 410:1120-1124.
18. Johnston S.R. New strategies in estrogen receptor positive breast cancer. Clin. Cancer Res. 2010, 16:1979-1987.
19. Brauch H., Jordan V.C. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the "personalised" approach?. Eur. J. Cancer 2009, 45:2274-2283.
20. Bouhoute A., Leclercq G. Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin. Biochem. Biophys. Res. Commun. 1992, 184:1432-1440.
21. San Jose E., Benguria A., Geller P., Villalobo A. Calmodulin inhibits the epidermal growth factor receptor tyrosine kinase. J. Biol. Chem. 1992, 267:15237-15245.
22. Li H., Villalobo A. Evidence for the direct interaction between calmodulin and the human epidermal growth factor receptor. Biochem. J. 2002, 362:499-505.
23. Aifa S., Johansen K., Nilsson U.K., Liedberg B., Lundstrom I., Svensson S.P. Interactions between the juxtamembrane domain of the EGFR and calmodulin measured by surface plasmon resonance. Cell. Signal. 2002, 14:1005-1013.
24. Yamane K., Toyoshima C., Nishimura S. Ligand-induced functions of the epidermal growth factor receptor require the positively charged region asymmetrically distributed across plasma membrane. Biochem. Biophys. Res. Commun. 1992, 184:1301-1310.
25. s. Arch. Biochem. Biophys. 2000, 383:309-317.
26. Aifa S., Aydin J., Nordvall G., Lundstrom I., Svensson S.P., Hermanson O. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. Exp. Cell Res. 2005, 302:108-114.
27. Li H., Sanchez-Torres J., Del Carpio A., Salas V., Villalobo A. The ErbB2/Neu/HER2 receptor is a new calmodulin binding protein. Biochem. J. 2004, 381:257-266.
28. Sacks D.B., Porter S.E., Ladenson J.H., McDonald J.M. Monoclonal antibody to calmodulin: development, characterization and comparison with polyclonal anti-calmodulin antibodies. Anal. Biochem. 1991, 194:369-377.
29. 2+/calmodulin and Cdc42 signaling. J. Biol. Chem. 1999, 274:464-470.
30. Li Z., Sacks D.B. Elucidation of the interaction of calmodulin with the IQ motifs of IQGAP1. J. Biol. Chem. 2003, 278:4347-4352.
31. s, in gonadotropin-releasing hormone receptor-mediated cell growth inhibition. Mol. Endocrinol. 2008, 22:2520-2530.
32. Norman J.A., Ansell J., Stone G.A., Wennogle L.P., Wasley J.W. CGS9343B, a novel, potent, and selective inhibitor of calmodulin activity. Mol. Pharmacol. 1987, 31:535-540.
33. Sanchez-Gonzalez P., Jellali K., Villalobo A. Calmodulin-mediated regulation of the epidermal growth factor receptor. FEBS J. 2010, 277:327-342.
34. Rhoads A.R., Friedberg F. Sequence motifs for calmodulin recognition. FASEB J. 1997, 11:331-340.
35. Jurado L.A., Chockalingam P.S., Jarrett H.W. Apocalmodulin. Physiol. Rev. 1999, 79:661-682.
36. Martin-Nieto J., Villalobo A. The human epidermal growth factor receptor contains a juxtamembrane calmodulin binding site. Biochemistry 1998, 37:227-236.
37. 669 within the juxtamembrane domain of the EGF receptor inhibits calmodulin binding. Biochem. Biophys. Res. Commun. 2006, 347:381-387.
38. 2+ mobilization. Proc. Natl Acad. Sci. USA 1997, 94:11627-11632.
39. 2+-independent calmodulin binding sites in erythrocyte protein 4.1. Implications for regulation of protein 4.1 interactions with transmembrane proteins. J. Biol. Chem. 2000, 275:6360-6367.
40. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
41. Adams J.A. Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model?. Biochemistry 2003, 42:601-607.
42. Bose R., Molina H., Patterson A.S., Bitok J.K., Periaswamy B., Bader J.S., Pandey A., Cole P.A. Phosphoproteomic analysis of HER2/Neu signaling and inhibition. Proc. Natl Acad. Sci. USA 2006, 103:9773-9778.
43. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of HER2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
44. Moasser M.M., Basso A., Averbuch S.D., Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001, 61:7184-7188.
45. Delord J.P., Allal C., Canal M., Mery E., Rochaix P., Hennebelle I., Pradines A., Chatelut E., Bugat R., Guichard S., Canal P. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease free survival in a micrometastasis model of ovarian carcinoma. Ann. Oncol. 2005, 16:1889-1897.
46. Piechocki M.P., Dibbley S.K., Lonardo F., Yoo G.H. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/Neu. Int. J. Cancer 2008, 122:1722-1729.
47. Tokunaga E., Kimura Y., Oki E., Ueda N., Futatsugi M., Mashino K., Yamamoto M., Ikebe M., Kakeji Y., Baba H., Maehara Y. Akt is frequently activated in HER2/Neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int. J. Cancer 2006, 118:284-289.
48. Park S.S., Kim S.W. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncol. Rep. 2007, 18:139-143.
49. Frankfurt O.S., Sugarbaker E.V., Robb J.A., Villa L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett. 1995, 97:149-154.